[go: up one dir, main page]

UY29727A1 - 7-aza-indazoles sustituidos, composiciones que les contienen, procedimientos de fabricación y utilización. - Google Patents

7-aza-indazoles sustituidos, composiciones que les contienen, procedimientos de fabricación y utilización.

Info

Publication number
UY29727A1
UY29727A1 UY29727A UY29727A UY29727A1 UY 29727 A1 UY29727 A1 UY 29727A1 UY 29727 A UY29727 A UY 29727A UY 29727 A UY29727 A UY 29727A UY 29727 A1 UY29727 A1 UY 29727A1
Authority
UY
Uruguay
Prior art keywords
aza
compositions
indazols
substituted
contain
Prior art date
Application number
UY29727A
Other languages
English (en)
Inventor
Souaille Catherine
Tabart Michel
Bjergardekirsten
Nair Anil
Patek Marcel
Ackerman-Berrier Martha
Smrcina Martin
Bacque Eeric
Ronan Baptiste
Leroy Vincent
Viviani Fabrice
Dodson Mark
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of UY29727A1 publication Critical patent/UY29727A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La prersente invención se refiere a nuevos 7-aza-indazoles especifícos que presentan una actividad moduladora de la actividad de las proteinas, en particular de la quinasas, a composiciones que les contienen, y a su utilización como medicamentos, en particular como agentes anticancerosos.
UY29727A 2005-08-04 2006-08-04 7-aza-indazoles sustituidos, composiciones que les contienen, procedimientos de fabricación y utilización. UY29727A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0508316A FR2889526B1 (fr) 2005-08-04 2005-08-04 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation

Publications (1)

Publication Number Publication Date
UY29727A1 true UY29727A1 (es) 2007-02-28

Family

ID=36177926

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29727A UY29727A1 (es) 2005-08-04 2006-08-04 7-aza-indazoles sustituidos, composiciones que les contienen, procedimientos de fabricación y utilización.

Country Status (29)

Country Link
US (1) US8058290B2 (es)
EP (1) EP1912988B1 (es)
JP (1) JP5128475B2 (es)
KR (1) KR101263970B1 (es)
CN (2) CN101304998B (es)
AR (1) AR057719A1 (es)
AU (1) AU2006277855B2 (es)
BR (1) BRPI0614304A2 (es)
CA (1) CA2617293C (es)
CR (1) CR9678A (es)
DO (1) DOP2006000179A (es)
EA (1) EA019302B1 (es)
EC (1) ECSP088152A (es)
FR (1) FR2889526B1 (es)
HN (1) HN2008000188A (es)
IL (1) IL188792A0 (es)
MA (1) MA29652B1 (es)
MX (1) MX2008001614A (es)
MY (1) MY147488A (es)
NI (1) NI200800020A (es)
NO (1) NO20081013L (es)
NZ (1) NZ565396A (es)
PE (1) PE20070240A1 (es)
TN (1) TNSN08024A1 (es)
TW (1) TWI378930B (es)
UA (1) UA94417C2 (es)
UY (1) UY29727A1 (es)
WO (1) WO2007017577A1 (es)
ZA (1) ZA200800965B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20061119A1 (es) * 2005-01-19 2006-11-27 Aventis Pharma Sa PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
EP2001880A2 (en) 2006-03-07 2008-12-17 Array Biopharma, Inc. Heterobicyclic pyrazole compounds and methods of use
US8931114B2 (en) 2008-09-22 2015-01-13 The United States Of America, As Represented By The Secretary Of The Navy Elastomeric composites with tether-containing, conducting polymers for nanoscale diffusion control
WO2010033966A1 (en) * 2008-09-22 2010-03-25 The Government of the United State of America, as represented by the Secretary of the Navy Tether-containing conducting polymers
JPWO2010125799A1 (ja) * 2009-04-27 2012-10-25 塩野義製薬株式会社 Ｐｉ３ｋ阻害活性を有するウレア誘導体
EP2789614B1 (en) 2009-08-11 2017-04-26 Bristol-Myers Squibb Company Azaindazoles as Btk kinase modulators and use thereof
PH12012500366A1 (en) 2009-08-24 2012-10-22 Ascepion Pharmaceuticals Inc 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors
US20120232062A1 (en) * 2009-10-20 2012-09-13 Eiger Biopharmaceuticals, Inc. Azaindazoles to treat flaviviridae virus infection
FR2954943B1 (fr) * 2010-01-07 2013-03-01 Sanofi Aventis Derives de pyridino-pyridinones arylsulfonamides, leur preparation et leur application en therapeutique
ES2528269T3 (es) * 2010-05-07 2015-02-06 Glaxosmithkline Llc Azaindazoles
WO2011160206A1 (en) 2010-06-23 2011-12-29 Morin Ryan D Biomarkers for non-hodgkin lymphomas and uses thereof
AU2011298987B2 (en) 2010-09-10 2017-09-28 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
EP2681216B1 (en) 2011-02-28 2017-09-27 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TWI598336B (zh) 2011-04-13 2017-09-11 雅酶股份有限公司 經取代之苯化合物
US9073924B2 (en) 2011-09-13 2015-07-07 Glaxosmithkline Llc Azaindazoles
EP2760862B1 (en) * 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US10138235B2 (en) 2011-12-14 2018-11-27 Sanofi Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof
FR2984325A1 (fr) * 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
BR112014025508B1 (pt) 2012-04-13 2020-11-17 Eisai R&D Management Co., Ltd. forma de sal de um inibidor de histona metiltransferase ezh2 humana
EP2847191B1 (en) 2012-05-09 2016-06-15 Sanofi Substituted 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors
JP6461803B2 (ja) 2012-10-15 2019-01-30 エピザイム，インコーポレイティド 置換ベンゼン化合物
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
TWI629275B (zh) * 2013-03-13 2018-07-11 賽諾菲公司 Ｎ－（４－（氮雜吲唑－６－基）－苯基）－磺醯胺及其作為醫藥之用途
EA038869B1 (ru) 2013-10-16 2021-10-29 Эпизим, Инк. Кристаллические формы гидрохлорида n-((4,6-диметил-2-оксо-1,2-дигидропиридин-3-ил)метил)-5-(этил(тетрагидро-2h-пиран-4-ил)амино)-4-метил-4'-(морфолинометил)-[1,1'-бифенил]-3-карбоксамида, фармацевтические композиции на их основе и способы их применения
BR112016029612B1 (pt) 2014-06-17 2021-01-19 Pfizer Inc. compostos de di-hidroisoquinolinona substituídos
US11059817B2 (en) 2015-09-23 2021-07-13 The Regents Of The University Of California Potent antiviral pyrazolopyridine compounds
CN107619388A (zh) * 2016-07-13 2018-01-23 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
CN107840842A (zh) 2016-09-19 2018-03-27 北京天诚医药科技有限公司 炔代杂环化合物、其制备方法及其在医药学上的应用
CN109715608B (zh) 2016-09-23 2022-08-05 诺华股份有限公司 在肌腱和/或韧带损伤中使用的吲唑化合物
JOP20190053A1 (ar) 2016-09-23 2019-03-21 Novartis Ag مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
WO2018106459A1 (en) 2016-12-07 2018-06-14 New Era Pharma, Inc. Compounds and pharmaceutical compositions for modulating sgk activity, and methods thereof
WO2019018562A1 (en) 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. AMIDO COMPOUND AS MODULATORS OF AHR
CN111138426B (zh) * 2018-11-02 2023-03-10 安徽中科拓苒药物科学研究有限公司 吲唑类激酶抑制剂及其用途
CN109456280B (zh) * 2018-12-24 2020-11-10 锦州医科大学 含有脲结构的4-苯基噻唑-2-胺类衍生物及其制备方法与应用
WO2020178316A1 (en) * 2019-03-05 2020-09-10 Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. S.P.A. 5- or 7-azaindazoles as beta-lactamase inhibitors
US11427558B1 (en) 2019-07-11 2022-08-30 ESCAPE Bio, Inc. Indazoles and azaindazoles as LRRK2 inhibitors
IL309118A (en) 2021-06-28 2024-02-01 Blueprint Medicines Corp CDK2 inhibitors
CN118561776A (zh) * 2024-05-15 2024-08-30 沈阳药科大学 一种n-(3-氟苄基)-1h-吲唑-5-胺衍生物及其用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1302287A (es) * 1970-07-21 1973-01-04
DE2538950A1 (de) * 1975-09-02 1977-03-03 Basf Ag Verfahren zur herstellung von 2,6- dichlor-nicotinsaeuren
DE2701610A1 (de) * 1977-01-17 1978-07-20 Basf Ag Farbstoffzubereitungen fuer cellulose und cellulosehaltiges textilmaterial und neue farbstoffe
DD154538A1 (de) * 1979-07-30 1982-03-31 Eberhard Schroetter Verfahren zur herstellung substituierter 2,4-und 2,6-dihalogen-pyridine
JPH04117362A (ja) * 1990-09-07 1992-04-17 Idemitsu Kosan Co Ltd ピリジン誘導体およびその塩ならびに該物質を有効成分とする殺虫・殺ダニ剤
AU7491400A (en) * 1999-09-17 2001-04-17 Abbott Gmbh & Co. Kg Kinase inhibitors as therapeutic agents
IL153997A0 (en) 2000-08-10 2003-07-31 Pharmacia Italia Spa Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
JP4272338B2 (ja) 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体
US6977262B2 (en) * 2001-02-02 2005-12-20 Mitsubishi Pharma Corporation Dihydropyrazolopyridine compounds and pharmaceutical use thereof
FR2827603B1 (fr) * 2001-07-18 2003-10-17 Oreal Composes derives de diaminopyrazole substitues par un radical heteroaromatique et leur utilisation en teinture d'oxydation des fibres keratiniques
CA2461363A1 (en) * 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
GB0128287D0 (en) 2001-11-26 2002-01-16 Smithkline Beecham Plc Novel method and compounds
WO2003068773A1 (en) * 2002-02-12 2003-08-21 Glaxo Group Limited Pyrazolopyridine derivatives
AU2003254051A1 (en) 2002-07-23 2004-02-09 Smithkline Beecham Corporation Pyrazolopyrimidines as kinase inhibitors
WO2004014368A1 (en) 2002-08-12 2004-02-19 Sugen, Inc. 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
SI1611131T1 (sl) 2003-02-27 2011-03-31 Palau Pharma Sa Pirazolopiridinski derivati
CN1809351A (zh) * 2003-04-24 2006-07-26 麦克公司 Akt活性抑制剂
CA2532800C (en) 2003-07-23 2013-06-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
JP4789622B2 (ja) 2003-09-16 2011-10-12 パナソニック株式会社 スペクトル符号化装置、スケーラブル符号化装置、復号化装置、およびこれらの方法
KR100703068B1 (ko) * 2003-12-30 2007-04-05 에스케이케미칼주식회사 피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물
GB0402137D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
WO2005110410A2 (en) 2004-05-14 2005-11-24 Abbott Laboratories Kinase inhibitors as therapeutic agents
FR2871158A1 (fr) * 2004-06-04 2005-12-09 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
WO2006076442A2 (en) 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives
PE20061119A1 (es) 2005-01-19 2006-11-27 Aventis Pharma Sa PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
ES2543607T3 (es) 2005-03-10 2015-08-20 Gilead Connecticut, Inc. Ciertas amidas sustituidas, método de obtención, y método de su uso
ES2545382T3 (es) * 2005-04-28 2015-09-10 Mitsubishi Tanabe Pharma Corporation Derivado de cianopiridina y su uso como medicamento
AU2006311422A1 (en) 2005-11-09 2007-05-18 Memory Pharmaceuticals Corporation 1 h-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof

Also Published As

Publication number Publication date
US8058290B2 (en) 2011-11-15
NZ565396A (en) 2011-03-31
EP1912988B1 (fr) 2014-04-16
ZA200800965B (en) 2009-11-25
TWI378930B (en) 2012-12-11
UA94417C2 (ru) 2011-05-10
MX2008001614A (es) 2008-04-04
JP5128475B2 (ja) 2013-01-23
EA019302B1 (ru) 2014-02-28
JP2009503037A (ja) 2009-01-29
FR2889526B1 (fr) 2012-02-17
HK1125928A1 (en) 2009-08-21
US20080182844A1 (en) 2008-07-31
MY147488A (en) 2012-12-14
AU2006277855B2 (en) 2012-08-23
AU2006277855A1 (en) 2007-02-15
CR9678A (es) 2008-09-22
IL188792A0 (en) 2008-08-07
PE20070240A1 (es) 2007-04-12
CN102093353B (zh) 2013-06-12
CA2617293A1 (fr) 2007-02-15
CN101304998B (zh) 2012-09-05
TW200745103A (en) 2007-12-16
CN101304998A (zh) 2008-11-12
NO20081013L (no) 2008-04-14
DOP2006000179A (es) 2007-03-31
ECSP088152A (es) 2008-02-20
AR057719A1 (es) 2007-12-12
HN2008000188A (es) 2010-11-09
KR20080031939A (ko) 2008-04-11
MA29652B1 (fr) 2008-07-01
KR101263970B1 (ko) 2013-05-13
FR2889526A1 (fr) 2007-02-09
EA200800514A1 (ru) 2008-06-30
EP1912988A1 (fr) 2008-04-23
TNSN08024A1 (en) 2009-07-14
NI200800020A (es) 2011-01-10
WO2007017577A1 (fr) 2007-02-15
CN102093353A (zh) 2011-06-15
CA2617293C (fr) 2015-09-22
BRPI0614304A2 (pt) 2011-03-22

Similar Documents

Publication Publication Date Title
UY29727A1 (es) 7-aza-indazoles sustituidos, composiciones que les contienen, procedimientos de fabricación y utilización.
ECSP088252A (es) 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización
UY29341A1 (es) Pirazolo piridinas sustituidas, composiciones que las contienen, procedimiento de fabricación
CR9463A (es) Pirrolinas sustituidas, composiciones que las contienen, proceso de fabricacion y utilizacion
CR9114A (es) 2-alcoxi-3,4,5-trihydroxi-alquimidas, su preparacion composicones que las contienen y su utilizacion
NI201000005A (es) Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico.
UY30276A1 (es) Dimeros de derivados de artemisinina, su preparacion y su aplicacion en terapéutica
UY29248A1 (es) Indoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización
CR9231A (es) Pirroles sustituidos, composiciones que los contienen, procesos de fabricacion y utilizacion
UY29361A1 (es) Pirroles e imidazoles sustituídos, composiciones que los contienen, procedimiento de fabricación y utilización
SV2006002384A (es) Pirazolo piridinas sustituidas, composiciones que las contienen, procedimiento de fabricacion y utilizacion
UY29999A1 (es) "n-pirazinil-fenilsulfonamidas, procedimientos y compuestos intemedios utilizados en su preparacion, composiciones farmaceuticas que las contienen y aplicaciones"
ES2422173T3 (es) Composiciones que contienen aecuorina y procedimientos de uso de las mismas
UY30368A1 (es) 2-alcoxi-3,4,5-trihidroxi-alquilamida-benzazepinas, su preparacion, composiciones que las contienen y utilizacion
CR10390A (es) Derivados de 2-alcoxi-3,4,5-trihidroxi-alquilamida, su preparacion, composiciones que las contienen y utilizacion
CR9115A (es) Indoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion
GT200700016A (es) 7-aza-indazoles sustituidos; composiciones que les contienen; procedimiento de fabricación y utilización.
ECSP088897A (es) 2-alcoxi-3,4,5-trihidroxi-alquilamida-benzotiazepinas, su preparación, composiciones que las contienen y utilización
DOP2005000246A (es) Indoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion
UY29235A1 (es) Bengamidas que poseen un ciclo caprolactama sustituido, procedimiento de preparación, composiciones que las contienen y utilización
UY29501A1 (es) Pirrolopiridinas sustituidas, composiciones que las contienen, proceso de fabricación y utilización

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160830